Mesothelioma research has focused on the specific challenges presented by the rare and fatal cancer caused by exposure to asbestos. But a team of Israeli scientists from a company called Accelerated Evolution Biotechnologies Ltd (AEBi) believes that it has found an innovative solution that will work for every type of cancer. They are beginning clinical trials and they believe that they can use it on patients within the next few years, and perhaps even sooner.
Multi-Target Toxin Attacks Cancer Cells From Multiple Angles
Dan Aridor says that he sees his cancer treatment being available for mesothelioma patients and other cancer patients soon. “We believe we will offer in a year’s time a complete cure for cancer,” he said. “Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market. Our solution will be both generic and personal.” The company calls their solution MuTaTo, a shortened description of “multi-target toxin.” They explain that it will act in a way similar to an antibiotic, but also compare it to the triple drug cocktail that has turned AIDS into a manageable disease. Where the drug combination disrupted the HIV virus at different stages in its replication, preventing it from bouncing back, MuTaTo will use customized phage displays based on each patient’s individual tumor’s DNA to quickly attack it from three different perspectives, thus arresting the cancer cells ability to mutate into a drug-resistant version of itself. It will specifically kill the cancer cells as well as cancer stem cells. This is a step that chemotherapy and other drugs that attack fast-growing cells skip. Morad explains that they have discovered how to use small-cell technology and, they will also be able to access cancer cells that other, large molecule medications are not able to access.
Treatment Offers Hope for Cancer Cell Death Without Side Effects
The new technology also eliminates one of the biggest drawbacks that exist for mesothelioma patients: the harmful side effects caused by most current cancer treatments. The MuTaTo solution specifically targets the cancer cells and will not attack healthy cells because they do not share the over expression of the protein that the medication will target. The scientists believe that once the cancer cells have been killed, patients will only have a few weeks of treatment.
Though the drug treatment has only been tested on lab animals and at a cellular level at this point, those tests have been successful enough to give hope to mesothelioma patients. The company will soon initiate clinical trials. If you need information on other treatment approaches that are available for mesothelioma patients, contact the Patient Advocates at Mesothelioma.net at 1-800-692-8608.